Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 13Sarcoma, Myeloid 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Promyelocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

fludarabine 25Cyclophosphamide 20Azacitidine 20venetoclax 18Specimen Handling 18fludarabine phosphate 17Mycophenolic Acid 14Melphalan 14Busulfan 14Biopsy 14Whole-Body Irradiation 13Tacrolimus 12Cytarabine 12Granulocyte Colony-Stimulating Factor 10decitabine and cedazuridine drug combination 9Decitabine 9Stem Cell Transplantation 8Sirolimus 8Injections 8Filgrastim 8Cyclosporine 8Peripheral Blood Stem Cell Transplantation 7Thiotepa 6ruxolitinib 5X-Rays 5Idarubicin 5Magnetic Resonance Spectroscopy 4Cladribine 4CPX-351 411-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Mitoxantrone × 90 days × Clear all
NCT03164057 2026-04-23

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
206 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03150004 2026-03-30

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Medical College of Wisconsin

Phase 2 Terminated
53 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡